Australian antiviral drug development company Island Pharmaceuticals Ltd (ASX:ILA) has announced that ISLA-101 has shown safety and anti-dengue activity in the Phase 2a cohort of the PROTECT Phase 2a/b trial.
Island Pharmaceuticals says ISLA-101 shows anti-dengue activity in Phase 2a study readout
November 27, 2024 Australian BiotechLatest Video
New Stories
-
Novartis partners with Advara HeartCare and TerryWhite Chemmart to launch Heart Health Collective,
December 6, 2024 - - Latest News -
Pfizer Australia launches Innovate Reconciliation Action Plan to advance equitable access to health and wellbeing
December 6, 2024 - - BioPharma -
Former CSL CEO Paul Perreault appointed strategic adviser to Microbio
December 5, 2024 - - Latest News -
More evidence backs the use of weight-loss therapies
December 5, 2024 - - Latest News -
ChatGPT would have produced more human responses than these committees
December 5, 2024 - - Latest News -
Anatara provides irritable bowel syndrome clinical trial update
December 4, 2024 - - Australian Biotech -
Digital health company Adherium secures R&D loan facility
December 4, 2024 - - Australian Biotech